Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis. [Review]

MedStar author(s):
Citation: Head & Neck. 41(8):2823-2829, 2019 08.PMID: 31162772Institution: MedStar Union Memorial HospitalDepartment: MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Antineoplastic Agents/tu [Therapeutic Use] | *Carcinoma, Neuroendocrine/dt [Drug Therapy] | *Sorafenib/tu [Therapeutic Use] | *Thyroid Neoplasms/dt [Drug Therapy] | Antineoplastic Agents/ae [Adverse Effects] | Carcinoma, Neuroendocrine/sc [Secondary] | Humans | Sorafenib/ae [Adverse Effects] | Thyroid Neoplasms/sc [Secondary]Year: 2019Local holdings: Available online from MWHC library: 1996 - presentISSN:
  • 1043-3074
Name of journal: Head & neckAbstract: CONCLUSION: Our results show that sorafenib treatment has a modest effect and might be a candidate treatment in patients with metastatic MTCs who have failed other therapeutic regimens.Copyright (c) 2019 Wiley Periodicals, Inc.INTRODUCTION: The aim of this study is to investigate and summarize the treatment efficacy and adverse effects (AEs) of sorafenib in the treatment of metastatic medullary thyroid carcinomas (MTCs).METHODS: We included studies reporting the treatment efficacy or drug toxicity of sorafenib as a single therapeutic agent in MTCs. Pooled incidence and its 95% confidence interval (CI) for complete response, partial response (PR), stable disease (SD), and sorafenib-related AEs were calculated using random-effect model.RESULTS: Eight trials with 101 metastatic MTCs were included for meta-analyses. The overall PR and SD were 21% (95% CI = 9-33) and 58% (95% CI = 41-75), respectively. Hand-foot syndrome, diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension were the most commonly observed AEs.All authors: Benekli M, Capdevila J, Ho ATN, Katoh R, Kondo T, Nakazawa T, Tran TTK, Vuong HGOriginally published: Head & Neck. 41(8):2823-2829, 2019 Aug.Fiscal year: FY2020Digital Object Identifier: Date added to catalog: 2019-06-21
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 31162772 Available 31162772

Available online from MWHC library: 1996 - present

CONCLUSION: Our results show that sorafenib treatment has a modest effect and might be a candidate treatment in patients with metastatic MTCs who have failed other therapeutic regimens.

Copyright (c) 2019 Wiley Periodicals, Inc.

INTRODUCTION: The aim of this study is to investigate and summarize the treatment efficacy and adverse effects (AEs) of sorafenib in the treatment of metastatic medullary thyroid carcinomas (MTCs).

METHODS: We included studies reporting the treatment efficacy or drug toxicity of sorafenib as a single therapeutic agent in MTCs. Pooled incidence and its 95% confidence interval (CI) for complete response, partial response (PR), stable disease (SD), and sorafenib-related AEs were calculated using random-effect model.

RESULTS: Eight trials with 101 metastatic MTCs were included for meta-analyses. The overall PR and SD were 21% (95% CI = 9-33) and 58% (95% CI = 41-75), respectively. Hand-foot syndrome, diarrhea, alopecia, mucositis, skin rash, fatigue, and hypertension were the most commonly observed AEs.

English

Powered by Koha